Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country

Nayyereh Ayati a, Monireh Afzali a, Mandana Hasanzad b, c, Abbas Kebriaeezadeh a, d, Ali Rajabzadeh e and Shekoufeh Nikfar a, c*

*Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran. bMedical Genomics Research Center, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran. cPersonalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. dDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran. eDepartment of Department of Industrial Management, Faculty of Management and Economics, Tarbiat Modares University, Tehran, Iran.

Abstract

Having multiple dimensions, uncertainties and several stakeholders, the costly pharmacogenomics (PGx) is associated with dynamic implementation complexities. Identification of these challenges is critical to harness its full potential, especially in developing countries with fragile healthcare systems and scarce resources. This is the first study aimed to identify most salient challenges related to PGx implementation, with respect to the experiences of early-adopters and local experts' prospects, in the context of a developing country in the Middle East. To perform a comprehensive reconnaissance on PGx adoption challenges a scoping literature review was conducted based on national drug policy components: efficacy/safety, access, affordability and rational use of medicine (RUM). Strategic option development and analysis workshop method with cognitive mapping as the technique was used to evaluate challenges in the context of Iran. The cognitive maps were face-validated and analyzed via Decision Explorer XML. The findings indicated a complex network of issues relative to PGx adoption, categorized in national drug policy indicators. In the rational use of medicine category, ethics, education, bench-to-bedside strategies, guidelines, compliance, and health system issues were found. Clinical trial issues, test's utility, and biomarker validation were identified in the efficacy group. Affordability included pricing, reimbursement, and value assessment issues. Finally, access category included regulation, availability, and stakeholder management challenges. The current study identified the most significant challenges ahead of clinical implementation of PGx in a developing country. This could be the basis of a policy-note development in future work, which may consolidate vital communication among stakeholders and accelerate the efficient implementation in developing new-comer countries.

Keywords: Pharmacogenomics; Precision medicine; Dynamic challenges; Policy note; Regulatory framework; Developing countries; Iran.
Introduction

Precision medicine (PM) is an approach that changes medical practice from reactive to proactive by using genomics and other omics characteristics of patients. Pharmacogenomics (PGx), as an extension of pharmacogenetics, is the leading area in the field of PM and studies the interactions between genetics and pharmaceutical treatments by applying in-vitro companion diagnostics (CDx). CDx makes it possible to draw a line between biomarker availability and targeted therapy, which may not only significantly increase the probability of effectiveness and safety profile of pharmaceutical treatments (1, 2) but may potentially reduce the overall costs of therapy. PGx is generally considered a cost-effective strategy by improving health outcomes and depending on the prevalence of the condition, relevant biomarkers, and cost of CDxs (3, 4). Therefore, notwithstanding the high costs, there is a growing global interest in it; even in developing low- and middle-income countries (LMIC) with fragile healthcare delivery schemes, constrained resources and unstable economies (5-9). This includes Iran, which may benefit from PGx treatment strategies as a country with a considerable burden of non-communicable diseases and high levels of genetic diversity (10, 11).

Clinical implementation of PGx, although may improve a daunting variety of health issues in the developing world by efficient treatment of a range of conditions from infectious to non-communicable diseases, as it is associated with multiple uncertainties, stakeholders, and dimensions, it may lead to enormous dynamic implementation and access hurdles (7). This includes, and is not limited to, the readiness of healthcare systems fundamentally and financially, governance, access, reimbursement plans, awareness, and data infrastructures, as stated by studies in other developing countries (12, 13).

To avoid implementation inefficiencies, there is a vital need for evidence-based policy notes and operational frameworks which indicate relative challenges, consolidate the vital confidence among stakeholders and state the steps towards an efficient implementation. Since PGx research and adoption is at their early stages in Iran and to avoid wastage of limited resources due to inefficient implementation, it is vital to address main concerns based on early adopters experiences and stakeholders’ expectations. Identification of public-policy concerns is the first step in developing an evidence-based roadmap (14), which can later be used by relevant decision-makers.

The current study aims to identify the most salient operational challenges related to the adoption of PGx in Iran concerning early adopters’ experience and experts’ expectations. This assessment is the first to address PGx implementation hurdles in the developing Middle-Eastern countries and could be the basis of the first evidence-based PGx policy-note and/or operational framework, in the future.

Experimental

Materials and Methods
Study Scope and Assessment Framework
Current qualitative study investigated the implementation challenges of PGx based on early adopters’ experience and localized them for Iran as a developing country. It used an assessment framework including four national drug policy (NDP) components which are (1) efficacy/safety/quality, (2) access/availability, (3) affordability, and (4) rational use of medicine (15) as the main research question, which was answered using an interpretive approach.

Evidence synthetization was through a scoping review, which is one of the methods for broad and emerging matters where knowledge gaps and unclarified concepts lie (16, 17), including the topic of PGx (12). The study framework for the current scoping review was based on a 6-step methodology presented by Arksey et al. in 2005 (18) and Levac et al. in 2010 (19), and the objective was to examine the nature of the evidence on the questioned matter. As PROSPERO did not accept registrations for scoping reviews at the time of the study, the protocol was not registered; however, it was conducted based on a 27-item PRISMA-2009 checklist, which is the most comprehensive checklist for secondary studies (20).
Data Sources, Search Limitations, and Study Selections

The search was conducted by two independent reviewers on Medline (via PubMed), Embase, ISI, Scopus, and Google Scholar, as selected scientific databases. Data extraction was conducted through three steps of title, abstract and full-text screening. Exclusive keywords used were “Pharmacogenomics”, “Pharmacogenetics”, “efficacy”, “safety”, “access”, “availability”, “affordability”, and “rational use of medicine”. The eligibility criteria were any original or systematic review journal article published between 2003 (the year of human genome sequencing completion) to 1.1.2020, which was English, had accessible full text, and discussed PGx implementation challenges. All identified studies were imported into the EndNote Basic software. Complete search strategies (syntaxes) are available in Annex 1. A data charting form was developed by the researcher and used to extract the classified data from full texts of selected studies through a more narrative review. Numerical analysis was conducted on the results. Also, a qualitative analysis was conducted on the characteristics of the included studies. As the main goal was to adopt all possible challenges issued through a scoping review, no quality assessment was performed.

Contextualization

To localize the categorized challenges in Iran, a focus group discussion with the strategic option development and analysis (SODA) workshop method was conducted. The reason for using SODA method and cognitive mapping technique was to better manage and extract the experts’ construct system on a dynamic matter which is associated with considerable uncertainties, multiple stakeholders, and many dimensions. This method was presented by Eden et al. in 2004 (21). Steps in this level were (1) information collection and primary elements assessment (PEA) through scoping review, which was explained in the previous step, (2) expert selection using list strategy, (3) focus group training with SODA workshop, (4) cognitive mapping and (5) data analysis.

For selecting experts, first, a list of experts was identified using the snowball selection method. In the snowball selection method, one person was selected initially, then recruited one additional subject, and the additional subject recruited another. Inclusion criteria were: 1) having a minimum of a PhD degree and 10-year relevant experience in at least one of the fields of genetics, pharmacogenomics, and Pharmacoeconomics, and pharmaceutical administration, 2) having relevant research on pharmacogenomics, and 3) having experience in an administrative or policy-making role at the pharmaceutical sector in the past five years. The list contained information including name, affiliation, phone number, and email of selected people. After preparing the list, 50% were picked randomly and were invited for the next steps by phone. Focus group training, using the SODA workshop method, was a two-hour pre-designed program in Tehran University of Medical Sciences which was an introductory to pharmacogenomics and the scoping review’s results. In the cognitive mapping step, ‘personal construct theory’ was practiced to capture personal construct systems and identify the expert’s values, beliefs and expectations of the dynamic issue at hand and use them to construct one aggregated system (21, 22). The cognitive maps were available to the subjects after the SODA workshop through email and was explained to them pre-completion through a one-hour meeting in Skype, individually. Data analysis was conducted with Decision Explorer XML (Demo Demonstration).

Validation

Face validation of semi-structured cognitive maps was conducted by two qualitative methodology experts, who were present in the pharmacogenomics SODA workshop.

Results

Scoping Review Results: A scientific database search resulted in 985 articles (Embase: 146, Scopus: 389, ISI: 126, PubMed: 204, and Google Scholar: 120). Among them, 795 remained after duplication removal, and 161, 107, and 82 articles were selected through the title, abstract, and full-text screening, respectively (Figure 1). The final selected studies were published between 2002 to 2019,
with 2013 having the most selected articles (n = 9, 11%). The majority of selected studies were conducted in The Unites States (n = 35, 42%) and Europe (n = 24, 29%, mainly Britain with n = 8, 9.75%).

All included studies assessed the implementation and regulatory challenges as the main purpose but from different perspectives. As a result of the scoping review, 15 categorized predominant issues, sub-categorized in four national drug policy indicators, were identified as follows: 3 on efficacy/safety, 3 on access and availability, 3 on affordability, and 6 regarding the rational use of medicine (RUM). The recurrence of the challenges is summarized in Table 1.

**Contextualization of Results**

PEAs were identified in the previous level and were used as the means of developing a semi-structured questioner, as the “personal construct theory” cognitive map. The snowball selection method identified 18 experts based on the inclusion criteria and list strategy. Among them, 8 were selected randomly. The male to female ratio of the participants were 1 and they had an average age of 48.6. All had a research history in the field of PGx (n = 8, 100%), three were clinicians with PhD degree and work/research experience in genetics, and PGx (n = 3, 37.5%) and five were pharmacists with PhD degrees in Pharmacoeconomics and pharmaceutical administration and had work experience in regulatory and policy-making roles in Iran’s FDA (n = 5, 62.5%). All participants participated in a 2-hour SODA training workshop, and a 1-hour individual session, and 7 (87.5%) completed the cognitive maps within the pre-defined timeline. The cumulated cognitive map is presented in Figure 2 with descriptive statistics in Table 2. These difficult-to-read kinds of maps, which include a complex network of node-labels and their connections, indicate the overall structure of the dynamic and complex problem and provide insight into it.
Table 1. Distribution of identified challenges, sub-categorized based on NDP components.

| Category                             | Issue                                                                 | Recurrence (N) | Recurrence (%) |
|--------------------------------------|----------------------------------------------------------------------|----------------|----------------|
| Rational Use of Medicine             | Ethical, legal and social issues                                     | 28             | 10.94          |
| (n = 103, 40.23%)                    | Efficient bench to bedside strategies                                | 14             | 5.47           |
|                                      | Guideline modifications                                             | 12             | 4.69           |
|                                      | Compliance                                                          | 7              | 2.53           |
|                                      | Electronic health records                                           | 5              | 1.95           |
|                                      | Education*                                                          | 37             | 14.4           |
|                                      | Clinical trial designs and modifications                           | 21             | 8.2            |
| Efficacy/Safety (n = 60, 23.44%)     | Clinical utility, validity and reliability of associated tests      | 33             | 12.89          |
|                                      | Biomarker discovery and validation                                  | 6              | 2.34           |
|                                      | Pricing and high costs                                             | 21             | 8.2            |
| Affordability (n = 52, 20.31%)       | Reimbursement                                                      | 16             | 6.25           |
|                                      | Health technology assessments                                       | 15             | 5.86           |
|                                      | Regulation (drug-test)                                              | 23             | 8.98           |
| Access (n = 41, 16.02%)              | Availability                                                        | 11             | 4.3            |
|                                      | Stakeholder management                                             | 7              | 2.73           |

*Among education-related challenges, 6.69% were related to the education of healthcare providers, 8.1% to regulators and 4.58% to the patient/public.

Figure 2. Collective cognitive map, indicating the multifaceted network of nodes and connections. Note: The map is not to be read. Dynamic challenges are centered around pharmacogenomics adoption, as the strategic goal. Main issues are shown in blue boxes; and sub-issues, clustered in gray circles are indicated in yellow boxes. PGx: pharmacogenomics.

Table 2. Descriptive statistics of the pharmacogenomics’ dynamic issues cognitive map.

| Measure                     | Number in the cognitive map |
|-----------------------------|-------------------------------|
| Concepts (nodes)            | 20                            |
| Links                       | 114                           |
| Heads                       | 1                             |
| Tails                       | 0                             |
| Strategic center(s)         | 1                             |
| Major (main) dynamic issues | 4                             |
| Minor (sub-) dynamic issues | 15                            |
| Central concepts > 10 links | 20*                           |
| Clusters                    | 4                             |
| Loops                       | 356                           |

*All concepts were central and included more than 10 links, with reimbursement and regulatory framework (16 links) being the most central and biomarker validation and discovery as the least (12 links).
Discussion

Overall, a growing interest regarding PGx was recognized globally and locally among various stakeholders. However, regarding the existence of potential dynamic challenges and lack of operational frameworks addressing them, PGx adoption is disorganized and slow, especially in fragile healthcare systems in LMIC developing countries.

The results of this study identified the most salient issues facing PGx adoption and presented a complex network of dynamic challenges, which requires fundamental planning to overcome to be established effectively. These challenges, which were identified through a qualitative approach, were categorized based on national drug policy components and are discussed below. The discussion order is based on the iteration of the challenges in the scoping review.

Rational use of medicine

Irrational use of medicine is characterized mainly in inefficient adoption of treatment approaches, and there are proven strategies to promote it, including continuing education, supervision, practical clinical guidelines, compulsory regulations, the existence of an essential drug list, and ethics. This category had the most iteration number of challenges and is included below:

Ethical, legal, and social issues

ELSIs were associated with the highest number of repetitions among all and were indicated to be amongst the most important challenges of PGx adoption in Iran. Studies showed that the main challenges in this field are autonomy, health-technology access disparities, use of special populations in research, and the risk of racial geneticization in pharmaceutical development (23-27). Access equity issues, especially when making the treatment only available to the strongest responded patients on social expenses, was another challenge (27, 28). This may also lead to more diversities between the developed comparing developing countries (27). In addition, some studies issued ethical concerns regarding PGx clinical trial designs, which emphasizes knowledgeable consents, the economic value from the societal perspective, the generalizability of results, selected population, use of genetically altered animals for pharming, adequate oversight to justify a human trial and recruitment justice (27, 29, 30).

Education, for healthcare providers, regulators, patients, and the public

The odds of irrational use of medicine may increase when introducing a new treatment strategy. Studies indicated that inadequate education of healthcare providers might appear as a barrier for efficient implementation of clinical PGx (31-37). Lack of education may also lead to irrational use of PGx-related testing (12, 38-40). A 2019 global survey on the progress of PGx education in medicine and pharmacy schools indicated that it is being seen as a necessity in a majority of study programs, and it has considerably improved in the last decade (41). It was indicated that public engagement and education may result in acceptance and adherence. Although this may be associated with some administrative challenges, education is a vital element in the transformation cycle and may enhance the effective implementation of PGx (42, 43).

PGx/CDx adherence and compliance

these were indicated in PEA's and addressed in two categories in the cognitive maps: healthcare providers and patients. Treatment adherence, as an effective factor in RUM, is defined as “the extent to which a person’s behavior corresponds with agreed recommendations from a healthcare provider” (44). A systematic review published in 2019 identified factors associated with non-adherence to pharmacotherapy among the patient population, naming socioeconomic status and education as effective factors (45). Educating patients and the general public on PGx and precision medicine principles, will elevate the efficiency of PGx implementation and lead to treatment adherence (42). In addition, studies suggest that PGx testing itself may enhance adherence by reducing the concern of patients regarding the effectiveness and safety of a treatment strategy. It satisfies the patient by active participation in the treatment selection based on the test results
and finally reducing the financial burden of trial and error (46-49). As for point of view of healthcare providers, a study showed that if physicians had comprehensive knowledge regarding PGx, molecular interpretation and test logistics (availability, cost, and coverage plans), it would increase their self-efficiency and enhance the implementation of PGx-testing (50).

Guideline development or modifications
Knowledge gaps and inadequate available information regarding PGx and test application is a concern of many clinicians, mainly due to the lack of comprehensive guidelines and also health information technology infrastructures (50-54). Studies suggest that the low rate of PGx implementation in clinical practice is due to the absence of transparent guidelines which can connect test results to clinical practice; therefore, some research networks such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) provided clinical guidelines to facilitate the bench to bedside transformation process for PGx (55, 56).

Electronic health records and clinical decision support
In order for a physician to commit to RUM principles when applying PGx information in clinical practice, precise and up to date information is necessary in terms of electronic health records (EHR), to rely on (55). This may work through three main mechanisms: retrospective valuation of information in clinical settings, novel associations in real-world cohorts, and finally, real-time clinical decision support (CDS) (57). CDS is recognized as a viable tool when the efficient implementation of PGx is in question. The development of a patient-centric CDS, which can collect, interpret and translate data to practical information, may perform as an efficient approach (58). It has been successfully applied in some settings (58-62); however, it is still a global and local need.

Bench to bedside strategies
Implementation of PGx test results in clinical practice is associated with overcoming all operational challenges and is a multi-disciplinary and multi-stakeholder scientific, cultural, and political act (53, 63-65). However, from the clinical-practice perspective, the most important factor is the availability of robust genomic data, which associates the test results to the right medicine. This information mainly comes from expensive clinical trials that show rare genetic variants and some may be subjected to lack of generalizability (66). In addition, as mentioned above, the absence of agreed-upon clinical guidelines, CDS tools, regulatory issues, education, and compliance may be barriers to transforming PGx from bench to bedside (55, 62, 64, 67, 68). To accelerate this process, CPIC had suggested standardization acts on three main areas: clinical laboratory regulations, outcomes reporting and coverage. These, alongside integrated EHR, would enhance both medical practice and patient care (69).

Efficacy/safety/quality-related challenges
Efficacy and safety are the first pillars to every drug policy. The current scoping review identified the following efficacy/safety-related challenges to be the main dynamic issues ahead of PGx and are discussed below:

Clinical trials' protocols
Efficacy and safety of personalized therapies are evaluated through clinical trials on biomarker-selected patients (70). Efficient adaptation of clinical trial protocols for evaluation of PGx medicinal products was one of the main stated challenges (70-73); however, as the pharmaceutical market in Iran is generic-based, not many clinical trials are conducted locally. Therefore, this challenge was identified as less important in Iran’s context based on the focus group opinion.

Biomarker discovery and validation
The identification and validation of Biomarkers is the key to clinical drug development and, accordingly efficient implementation of pharmacogenomics. However, their value depends on clinical utility and can be transformed into clinical use (74, 75). Despite advances in biomarker research, the translation of biomarkers into approved CDx is relatively low (76). This was identified as a challenge in the scoping review but again had minor importance in the context of Iran.
Clinical utility and validity of test results

Clinical utility of pharmacogenomics testing could be seen in prognostic and predictive test values. Data gaps in basic science, validity of biomarker translation, and lack of technological testing conditions may affect the clinical utility of pharmacogenomics testing. Accordingly, validation, scoring criteria, assay protocols, preservation methods, bio-specimen type selection, variation in patients’ drug regimens, and reporting quality may cause scientific and implementation challenges in PGx testing (75).

Access

Given the rising prices and constantly altering market, equitable access to quality health goods is a global multidimensional and multi-stakeholder challenge. According to WHO 2019-2023 roadmap on access to health products, there are two interlinked strategic components to access: equity improvement and efficiency assurance. This may be challenged due to scarce resources and unclear policy frameworks, among other barriers. As for PGx, equal access to effective medicines and CDxs is essential; however, some challenges such as lack of comprehensive frameworks, availability, stakeholder communication, affordability issues, and ELSIs may challenge access.

Regulatory frameworks

As pharmaceuticals directly affect the lives of humans, governments need to ensure that the development, access, and use of medicines is regulated. This includes research/development, manufacturing, distribution, promotion/advertisement, marketing, import/export, supply chain, market inspection, drug labeling, and pharmacovigilance (77-79). The main hurdle facing regulatory agencies was the need for the regulatory schemes to adopt the new PGx/CDx requirements (80). Although there are different regulatory operational frameworks for PGx medicinal products and CDxs (81, 82), there are integrated ones which present linked legislation for PGx medicinal products and CDxs focusing on resolving pre-defined challenges in a distinct context or country (83-86). There is currently no PGx regulation framework in Iran; however, this study aims to be the first step in developing such a structure.

Availability

A handful of studies discussed the availability challenges for genomics-based pharmaceuticals and companion diagnostics (83-85, 87-92). However, based on the contribution from experts, availability is a considerable challenge in Iran. This is due to approval and the registration time-gap between the US and Iran’s FDA, for both pharmaceuticals and CDxs. By April 2020, there were 280 PGx-labeled FDA-approved pharmaceuticals. Among them, 122 (43.5%) were available on Iran’s drug list, which gained approval with a mean time gap of 12.36 years (99% confidence interval: 1-59, Annex 2) (93). This increases when CDxs are concerned; mainly due to the lack of co-development or drug-test registration time-gaps (94-96). As there is no governmental list of registered diagnostics in Iran, availability and registration time gap cannot be estimated. In addition, although some of CDxs are available in Iran, they are not available in core primary care centers in all cities and will challenge patient access. Co-approval of CDxs may increase their availability (89).

Stakeholder communication

Implementation of PGx is a dynamic issue that requires communication between stakeholders; who may have different views and levels of awareness (12). Multiple stakeholders are associated with PGx implementation in Iran, naming: healthcare providers, patients, regulators, clinical associations, payers, investors, and the government as the owner. Some studies discuss the involvement of different stakeholders and their alliance in the process of an effective translation and implementation (83, 97). Among them, there is emphasis on the engagement of the general public, as the core beneficiary and the primary funder, and discovering their expectations and perception towards PGx (83, 98, 99).

Affordability

Implementation of pharmacogenomics and applying tests in a specific condition is highly dependent on whether the total value is higher...
than the total costs in a given setting with limited resources (100). Issues included in this category are discussed below:

**Pricing and high costs**

In the pharmaceutical and the diagnostics industries, which both have innovative and fast-growing markets, the revenue of goods is required to be in balance with the R&D costs and also the other value associated with that good; however, since the value may change based on time and context, the value-based price needs to be flexible (101). Value-based pricing is currently a well-known pricing method for pharmaceuticals, but diagnostics are mostly priced based on the cost-plus method and therefore may have low prices (40). Lower prices, especially in niche markets, lead to market negligence on some disease areas and harvests unmet needs. In some countries, the government incentivizes innovation in these areas by fast-tracking approvals, tax exemptions, grants, or market exclusivity (102, 103).

**Reimbursement**

Reimbursement supports patient access to novel health goods, especially those with high costs such as medicines and CDxs. In recent years, this financial contribution shifted towards outcome-based and risk-sharing payment models. These models are beneficial for manufacturers who can demonstrate the comparative value of their products and enable them to acquire extensive coverage and payer acceptance (104, 105). However, this requires strong administrative support and a follow-up database, which is not available in some countries, including Iran. In addition, the value of the companion diagnostics is not fully appreciated by health systems, and their market access framework is not fully aligned with drug-test co-reimbursement plans; therefore, patient affordability and eventually access would be affected (90, 106). From the payer perspective, although there are upsides to diagnostic coverage, including cost avoidance for non-responders and enhanced patient outcomes, there are also risks due to increased expenses for false results, an expanded patient population, and budget increases (104). In addition, fundamental ethical issues may appear when utilizing the results of Pharmacoeconomics studies for budget allocation decisions (107). A comprehensive review of the coverage policies of early adopters, for both PGx-medicines and CDx, is crucial for a developing country with scarce financial resources. Currently, in Iran, although some PGx-medicines are covered by insurance, no CDx is reimbursed by payers.

**Health Technology Assessments**

When appraising the value of health technologies, both scientific and social values should be assessed during the early stages of drug development as the clinical effectiveness alone is not sufficient for the value judgment (108). The comparative economic evaluation for PGx and CDx (as a tool) lies on value demonstration in terms of incremental net health benefit and/or cost-effectiveness ratio, based on decision-makers’ objectives. This economic evaluation is associated with methodological, parameter, and structural uncertainties (109). It also may be subjected to issues regarding preciseness of the study question, identifying the place of intervention in the clinical pathway, data availability, and physicians’ compliance to uptake CDx (3, 110, 111). CDx may reduce patient-level heterogeneity, and cost/consequence of this reduction must be considered in the economic evaluations (109).

In addition to cost-effectiveness analysis, a budget impact analysis should be conducted for PGx-medicines and CDxs. It encompasses considerable financial burdens on healthcare systems and continued increases of the concerns on the sustainability of equitable and affordable access (12). This is important, especially in developing countries with very limited healthcare resources. In Iran, HTAs are mandatory for the Iran drug list and insurance basic list entry; however, it is not the routine for companion diagnostics registration or coverage.

The current study’s method was similar to some other studies (12, 14, 112). Chong HY et al. used scoping review and main stakeholder interviews to identify the landscape and the challenges of the PM adoption in the context of Southeast Asia. In this analysis, the assessment framework was based on a
developed theme with six key indicators of health system, governance, access, awareness, implementation and data; while in the current study barriers were categorized based on NDP components. Chong H. Y. et al. study identified potential hazard for health disparities, lack of awareness, and political/financial supports to be the most prominent barriers for efficient implementation (12). Bashir NS et al. study, which was conducted to reach a policy framework on PGx testing in Canada, used scoping review to identify all the relevant barriers. These barriers were genetic discrimination, clinical trials, privacy, knowledge, stakeholder roles and clinical utility of tests. Also, it further utilized a policy development framework (3-I) to develop PGx policy. In contrast to the current, this study did not use a contextualization method to localize the results (14). Rafi I et al. used a qualitative study, including semi-structured interviews, to identify opportunities and barriers of PGx implementation into the United Kingdom clinical practice. In this study, which only used interviews as the source of data, interviewees were clinicians; however, the SODA workshop and individual cognitive maps were completed by multiple stakeholders in different sectors. The results of the Rafi et al. study showed that cost-effectiveness, availability, and ELSI of using genetic information in the primary care were the most salient issues (112).

The current study is subjected to a few but important limitations; first, based on the broadness of the topic and due to the scoping review method (18, 19), quality assessment was not conducted on the selected studies. Second, the contextualization step and expert selection were conducted through the snowball approach, it may have been associated with selection bias, despite the random list strategy. However, as all participated experts were researchers experienced in health policymaking or pharmaceutical regulations, and also with adequate knowledge regarding PGx, it is believed that the significant implementation challenges are captured.

Conclusion

Despite the growing interest in the novel PGx era, even in developing countries with scarce resources, not enough is known about the possible hurdles facing efficient and evidence-based adoption of PGx to harness its full potential. In the current study, more salient challenges were identified through the experience of early adopters and the expectations of experts. The complex network of dynamic issues identified in the current study could be set as the matter of precedence and be the basis of the first pharmacogenomics policy note in the future. Although this study was conducted in the context of Iran, the findings could be extrapolated and used by developing middle-eastern countries where emerging interest in PGx adoption is expected.

Future Perspective

There is an increasing interest in Pharmacogenomics globally, including developing low-middle-income countries that have limited budgets. Therefore, it is predicted that in a few years, drug research and also treatment approach will shift towards pharmacogenomics. This, makes it more vital to have updating pre-existing roadmaps and policy notes to harness this shift’s full potential.

Acknowledgements

The current study was a part of PhD thesis of Nayyereh Ayati (first author) and was approved by Specialized Research Council of Tehran University of Medical Sciences (TUMS). The authors are grateful to the TUMS Specialized Research Council for reviewing the article. Also, research reported in this publication was supported by Elite Researcher Grant Committee under award number 963500 from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran.

Conflict of Interests

The authors declare no conflict of interest.

Author Contributions

All authors were involved in the conception and design of the study, collection of the data, analysis, and interpretation of the data, drafting of the article, and the provision of
final approval of the article for submission/publication in the current journal. All authors agree to be accountable for all aspects of this work.

References

(1) Johnson JA and Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin. Pharmacol. Ther. (2016) 99: 154-6.

(2) Charlab R and Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol. Biol. (2013) 1015: 3-22.

(3) Kasztura M, Richard A, Bempong NE, Loncar D and Flahault A. Cost-effectiveness of precision medicine: a scoping review. J. Public Health (Oxf). (2019) 64: 1261-71.

(4) Plöthner M, Ribbentrop D, Hartman J-P and Frank M. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv. Ther. (2016) 33: 1461-80.

(5) Tekola-Ayele F and Rotimi CN. Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genomics. (2015) 18: 242-7.

(6) Ghaddar F, Saba K and Zgheib N. Teaching pharmacogenetics in low and middle income countries (LMICS): an empirical study of the lessons learned. Curr. Pharmacogenomics Pers. Med. (2012) 10: 217-25.

(7) Pang T. Pharmacogenomics and personalized medicine for the developing world - too soon or just-in-time? a personal view from the world health organization. Curr. Pharmacogenomics Pers. Med. (2009) 7: 149-57.

(8) Patrinos GP, Pasparakis E, Koiliari E, Pereira AC, Hünemeier T, Pereira LV and Mitropoulou C. Roadmap for establishing large-scale genomic medicine initiatives in low- and middle-income countries. Am. J. Hum. Genet. (2020) 107: 589-95.

(9) Mitropoulos K, Al Jaibeji H, Forero DA, Laisseau P, Wonkam A, Lopez-Corrao C, Mohamed Z, Chantratita W, Lee MTM, Llerena A, Brand A, Ali BR and Patrinos GP. Success stories in genomic medicine from resource-limited countries. Hum. Genomics. (2015) 9: 11.

(10) Khorrami Z, Rezapour M, Etemad K, Yarahmadi S, Khodakarim S, Mahdavi Hezaveh A, Kameli M and Khamjani N. The patterns of non-communicable disease multimorbidity in Iran: A multilevel analysis. Sci. Rep. (2020) 10: 3034.

(11) Mehrjoo Z, Fattahi Z, Beheshtian M, Mohseni M, Poustiti H, Ardalani F, Jalalvand K, Arzhangi S, Mohammadzadeh A, Fajer S, Najafi F, Nikuei P, Haddadi M, Zohrehvand E, Oladnabi M, Mohammadzadeh A, Safari MH, Akhtarkhavari T, Goosksh ES, Haghdooost A, Najafipour R, Niestroj LM, Helwing B, Gaoamann Y, Toliat MR, Malekzadeh R, Nürnberg P, Kahrizi K, Najamabadi H and Nothnagel M. Distinct genetic variation and heterogeneity of the Iranian population. PLoS Genet. (2019) 15: e1008385.

(12) Chong HY, Alloetey PA and Chaiyakanapruk N. Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Genom. (2018) 11: 1-15.

(13) Warnich L, I Drogemoller B, S Pepper M, Dandara C and EB Wright G. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr. Pharmacogenomics Person. Med. (2011) 9: 191-207.

(14) Bashir NS and Ungar WJ. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. Genome. (2015) 58: 527-40.

(15) Nikfar S, Kebriaeazzadeh A, Majdzadeh R and Abdollahi M. Monitoring of national drug policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int. Health Hum. Rights. (2005) 5: 5.

(16) Munn Z, Peters MD, Stern C, Tunafaru C, McArthur A and Aromatirios EJbmr. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol. (2018) 18: 143.

(17) Peters MJr, Godfrey CM, Khalil H, McNerney P, Parker D and Soares CB. Guidance for conducting systematic scoping reviews. Int. J. Evid. Based Healthc. (2015) 13: 141-6.

(18) Arksey H and O’Malley LJIjosrm. Scoping studies: towards a methodological framework. Int. J. Soc. Res. Methodol. (2005) 8: 19-32.

(19) Levac D, Colquhoun H and O’Brien KJKJs. Scoping studies: advancing the methodology. Implement. Sci. (2010) 5: 69.

(20) Moher D, Liberati A, Tetzlaff J and Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. (2010) 8: 336-41.

(21) Eden C and Ackermann F. Cognitive mapping expert views for policy analysis in the public sector. Eur. J. Oper. Res. (2004) 152: 615-30.
(22) Neimeyer RA and Levitt H. Constructivism/Constructionism: Methodology. In: Smelser NJ and Baltes PB (eds.) International encyclopedia of the social & behavioral sciences. Oxford: Pergamon; (2001) 2651-4.

(23) Callier SL, Abudu R, Mehlman MJ, Singer ME, Neuhauser D, Caga-Anan C and Wiesner GL. Ethical, legal, and social implications of personalized genomic medicine research: current literature and suggestions for the future. Bioethics. (2016) 30: 698-705.

(24) Lee S. Pharmacogenomics and the challenge of health disparities. Public Health Genom. (2009) 12: 170-9.

(25) Lee SS-J. Racializing Drug design: implications of pharmacogenomics for health disparities. Am. J. Public Health. (2005) 95: 2133-8.

(26) Marx-Stolting L. Ethical implications of pharmacogenomics: shaping the future of the field. Curr. Pharmacogenomics. (2006) 4: 261-9.

(27) Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J. (2003) 3: 194-6.

(28) Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipes. N. Biotechnol. (2012) 29: 757-68.

(29) Gupta S, Smith TR and Broekman ML. Ethical considerations of neuro-oncology trial design in the era of precision medicine. Neuro-Oncol. (2017) 134: 1-7.

(30) Shields AE. Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. Addict. Sci. Clin. Pract. (2011) 6: 32-43.

(31) McKinnon RA, Ward MB and Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. (2007) 3: 751-9.

(32) Johansen Taber K and Dickinson B. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmacogenomics Pers. Med. (2014) 7: 145.

(33) Marciniak R, Paris M and Kinney SRM. Pharmacogenomics education improves pharmacy student perceptions of their abilities and roles in its use. Am. J. Pharm. Educ. (2018) 82: 6424.

(34) Frueh FW and Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics. (2004) 5: 571-9.

(35) Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM and Johnson JA. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacol. (2014) 34: 1102-12.

(36) Weitzel KW, Aquilante CL, Johnson S, Kisor DF and Empey PE. Educational strategies to enable expansion of pharmacogenomics-based care. Am. J. Health-Syst Pharm. (2016) 73: 1986-98.

(37) Yau A, Abd Aziz AB and Haque M. Knowledge, attitude and practice concerning pharmacogenomics among pharmacists: A systematic review. J. Young Pharm. (2015) 7: 145-54.

(38) Bombard Y, Rozmovits L, Trudeau M, Leigh NB, Deal K and Marshall DA. The value of personalizing medicine: medical oncologists’ views on gene expression profiling in breast cancer treatment. Oncol. J. (2015) 20: 351-6.

(39) Brall C and Schröder-Bäck P. Personalised medicine and scarce resources: a discussion of ethical chances and challenges from the perspective of the capability approach. Public Health Genomics. (2016) 19: 178-86.

(40) Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A-P, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towe A, Veenstra D, Watkins J and Personalized medicine development and Reimbursement working group. Challenges in the development and Reimbursement of personalized medicine—Payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group. Value Health. (2012) 15: 1162-71.

(41) Karas Kuželički N, Prodan Žitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, Ansari M, Pazzagli M, Resta CD, Brandslund I, Schwab M, Vermeersch P, E Lunshof J, Dedoussis G, S Forderliss C, Fuhr U, C Stingl J, van Schaik RHN, G Manolopoulos V, Marc J and the pharmacogenomics education working group (PGxEWG). Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics. (2019) 20: 643-57.

(42) Etchégary H and Wilson B. Bringing personalized medicine to the community through public engagement. J. Pers. Med. (2013) 10: 647-59.

(43) Frueh FW, Goodsaid F, Rudman A, Huang SM and Lesko LJ. The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J. (2005) 5: 218-20.

(44) Çelik E, Şencan MN and Clark MP. Factors affecting rational drug use (RDU), compliance and wastage. Turkish J. Pharm. Sci. (2013) 10.

(45) Gast A, Mathes T. Medication adherence
influencing factors—an (updated) overview of systematic reviews. Syst. Rev. (2019) 8: 112.

(46) Haga SB and LaPointe NMA. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J. (2013) 13: 481-3.

(47) Charland SL, Agatep BC, Herrera V, Schrader B, Frueh FW, Ryvkin M, Shabbeer J, Devlin JJ, Superko HR and Stanek EJ. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J. (2013) 14: 272-80.

(48) Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM and Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia (2009) 52: 2299-305.

(49) Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreu K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ and O’Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. (2019) 19: 528-37.

(50) Heale BSE, Khalifa A, Stone BL, Nelson S and Del Fiol G. Physicians’ pharmacogenomics information needs and seeking behavior: a study with case vignettes. BMC Med. Inform. Decis. Mak. (2017) 17: 113.

(51) Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, Hindroff LA, Jarvik G, Karavite D, Lebo M, Plon SE, Allen EV, Weck KE, White PS and Yang Y. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet. Med. (2013) 15: 824-32.

(52) Devine EB, Lee C-J, Overby CL, Abernethy N, McCune J, Smith JW and Tarczy-Hornoch P. Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. Int. J. Med. Inform. (2014) 83: 473-83.

(53) Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, brilliant MH, Eng C, Frazer KA, Kolb B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O’Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED and Ginsburg GS. Implementing genomic medicine in the clinic: the future is here. Genet Med. (2013) 15: 258-67.

(54) Overby CL and Tarczy-Hornoch P. Personalized medicine: challenges and opportunities for translational bioinformatics. J. Pers. Med. (2013) 10: 453-62.

(55) Relling MV and Klein TE. CPIC: Clinical Pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. (2011) 89: 464-7.

(56) Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk A-M, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilfert B, Deneer VHM, Guchelaar HJ and on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic information in clinical guidelines: The European perspective. Clin. Pharmacol. Ther. (2018) 103: 795-801.

(57) Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J and Savova G. The emerging role of electronic medical records in pharmacogenomics. Clin. Pharmacol. Ther. (2011) 89: 379-86.

(58) Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE and Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am. J. Health-Syst. Pharm. (2016) 73: 1967-76.

(59) Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV and Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. (2014) 21: e93-9.

(60) Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A and Detmer DE. A roadmap for national action on clinical decision support. J. Am. Med. Inform. Assoc. (2007) 14: 141-5.

(61) Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schilderout J, Gregg W, Johnson K, Jirjis JN, Roden DM, Pulley JM and Denny JC. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet. Med. (2013) 15: 833-41.

(62) Welch BM and Kawamoto K. Clinical decision support for genetically guided personalized medicine: a systematic review. J. Am. Med. Inform. Assoc. (2013) 20: 388-400.

(63) H Hippman C and Nilso1 C. Pharmacogenomic testing: clinical evidence and implementation challenges. J. Pers. Med. (2019) 9: 40.

(64) Rosenman MB, Decker B, Levy KD, Holmes AM,
Pratt VM and Eadon MT. Lessons learned when introducing pharmacogenomic panel testing into clinical practice. *Value Health.* (2017) 20: 54-9.

Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I and Khoueiry Zgeb N. Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. *Br. J. Clin. Pharmacol.* (2019) 85: 2076-88.

Dong OM and Wiltshire T. Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. *Physiol. Genomics.* (2017) 49: 346-54.

Dias MM, Sorich MJ, Rowland A, Wiese MD and McKinnon RA. The routine clinical use of pharmacogenetic tests: what it will require? *Pharm. Res.* (2017) 34: 1544-50.

Mohamed AH. Pharmacogenomics translation; From bench to bedside. *Drug Metab. Pharmacokinet.* (2013) 28: A33-4.

Caudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM and Hoffman JM. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. *Pharmacogenomics.* (2018) 19: 847-60.

Aguilar H, Sanchez E, Braña I, Vivancos A and Rodon J. Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials. *Expert Rev. Precis. Med. Drug Dev.* (2016) 1: 419-30.

Rodon J, Soria JC, Berger R, Batist G, Tsimeridou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V and Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINThER, a Worldwide Innovative Network (WIN) Consortium trial. *Ann. Oncol.* (2015) 26: 1791-8.

Saad ED, Paolotti X, Burzykowski T and Buyse M. Precision medicine needs randomized clinical trials. *Nat. Rev. Clin. Oncol.* (2017) 14: 317-23.

Vivot A, Li J, Zeitoun J-D, Mourah S, Crecuit P, Ravaud P and Porcher R. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. *Genet. Med.* (2015) 18: 796-805.

Trepicchio WL and Mulligan G. Translation of biomarkers into clinical utility. *Pharmgenomics Pers Med.* Springer (2008) 239-51.

Barsanti-Innes B, Hey SP and Kimmelman J. The challenges of validating in precision medicine: the case of excision repair cross-complement group 1 diagnostic testing. *Oncol. J.* (2017) 22: 89.

McDermott JE, Wang J, Mitchell H, Webb-Robertson B-J, Hafen R, Ramey J and Rodland KD. Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. *Expert Rev. Med. Devices* (2013) 7: 37-51.

Rägo L, Sillo H, ’t Hoen E and Zweygarth M. The financial hazard of personalized medicine products: evaluation of alignment. *Pharmacogenomics J.* (2017) 17: 121-7.

Prasad K and Breckenridge A. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. *Drug Discov. Today* (2011) 16: 867-72.

Hopkins M. Regulatory and Quality Assurance Frameworks for PGX: A Comparative Study of the US, EU and Four EU Member States. (2006) [cited 2019 April, 17]. Available from: URL: https://www.york.ac.uk/rgc/pbgx/publications/eur22214wp3.pdf.

Nimmesgern E, Norstedt I and Draghia-Akli R. Enabling personalized medicine in Europe by the European Commission’s funding activities. *J. Pers. Med.* (2017) 14: 355-65.

Bombard Y, Abelson J, Simeonov D and Gauvin F-P. Citizens’ perspectives on personalized medicine: a qualitative public deliberation study. *Eur. J. Hum. Genet.* (2013) 21: 1197-201.

Browman GP, Vollmann J, Virani A and Schildmann J. Improving the quality of ‘personalized medicine’ research and practice: through an ethical lens. *J. Pers. Med.* (2017) 11: 413-23.

Budin-Ljøsne I and Harris JR. Patient and interest organizations’ views on personalized medicine: a qualitative study. *BMC Med. Ethics* (2016) 17: 1-10.

Weda M, Kienhuis A, van der Heyden L, Matic M, Rodenburg W, van Drongelen A and Janssen S. Personalised medicine products: evaluation of the regulatory framework. (2014) Available from: URL: https://www.rivm.nl/bibliotheek/rapporten/360211001.pdf.

Carrera PM and Olver I. The financial hazard of personalized medicine and supportive care. *Support. Care Cancer.* (2015) 23: 3399-401.

Carroll JC, Makuwaza T, Manca DP, Sopcak N,
Permaul JA, O’Brien MA, Heisey R, Eisenhauer EA, Easley J, Kryzanowska MK, Miedema B, Pruthi S, Sawka C, Schneider N, Sussman J, Urquhart R, Versaevel C and Grunfeil E. Primary care providers’ experiences with and perceptions of personalized genomic medicine. Can. Fam. Physician. (2016) 62: E626-35.

(89) Shimazawa R and Ikeda M. Approval gap of pharmacogenomic biomarkers and in-vitro companion diagnostics between the United States and Japan. J. Clin. Pharm. Ther. (2014) 39: 210-4.

(90) Wurcel V, Perche O, Lesteven D, Williams D-A, Schäfer B, Hopley C, Jungwirth R, Postulka A, Pasmans R, Hermansson LL, Ott M and Glorioso V. The value of companion diagnostics: overcoming access barriers to transform personalised health care into an affordable reality in Europe. Public Health Genom. (2016) 19: 137-43.

(91) Buzyn A, Blay J-Y, Hoog-Labouret N, Jimenez M, Nowak F, Deley M-CL, Pérol D, Cailliot C, Raynaud J and Vassal G. Equal access to innovative therapies and precision cancer care. Nat. Rev. Clin. Oncol. (2016) 13: 385-93.

(92) Schilsky RL. Implementing personalized cancer care. Nat. Rev. Clin. Oncol. (2014) 11: 432-8.

(93) Administration IFD. National Formulary Information: Iran Food and Drug Administration. (2020) [cited 2020 March , 30]. Available from: URL: WWW.FDA.GOVTIR.

(94) Cohen J, Wilson A and Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. (2012) 13: 378-88.

(95) Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin. Cancer Res. (2014) 20: 1453-7.

(96) Pacanowski MA, Leptak C and Zineh I. Next-generation medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. (2014) 95: 247-9.

(97) Hudson TJ. Personalized medicine: A transformative approach is needed. Can. Med. Assoc. J. (2009) 180: 911-3.

(98) Nielsen LF and Moldrup C. Lay perspective on pharmacogenomics: a literature review. J. Pers. Med. (2006) 3: 311-6.

(99) Abelson J, Giacomini M, Lehoux P and Gauvin F-P. Bringing ‘the public’ into health technology assessment and coverage policy decisions: from principles to practice. Health Pol. (2007) 82: 37-50.

(100) Wedlund PJ and de Leon J. Pharmacogenomic testing: the cost factor. Pharmacogenomics J. (2001) 1: 171-4.

(101) Garrison L and Towe A. Value-based pricing and reimbursement in personalised healthcare: introduction to the basic health economics. J. Pers. Med. (2017) 7: 10.

(102) Gibson S, Razee HR and Lemmens T. Why the shift? taking a closer look at the growing interest in niche markets and personalized medicine. World Med. Health Policy. (2015) 7: 3-27.

(103) Keeling P. Personalized medicine: the absence of ‘model-changing’ financial incentives. J. Pers. Med. (2007) 4: 73-81.

(104) Akhmetov I and Bubnov RV. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? EPMA J. (2017) 8: 5-15.

(105) Antoñanzas F, Rodriguez-Ibeas R and Juárez-Castelló CA. Personalized medicine and pay for performance: should pharmaceutical firms be fully penalized when treatment fails? PharmacoEconomics. (2018) 36: 733-43.

(106) Hresko A and Haga S. Insurance coverage policies for personalized medicine. J. Pers. Med. (2012) 2: 201-16.

(107) La Caze A. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? PharmacoEconomics. (2005) 23: 445-7.

(108) Rawlins MD and Culyer AJ. National institute for clinical excellence and its value judgments. Br. Med. J. (2004) 329: 224-7.

(109) Gavan SP, Thompson AJ and Payne K. The economic case for precision medicine. Expert Rev. Precis. Med. Drug Dev. (2018) 3: 1-9.

(110) Shabaruddin F, Payne K and Fleeman N. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers. Med. (2015) 8: 115.

(111) Buchanan J, Wordsworth S and Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics (2013) 14: 1833-47.

(112) Rafi I, Crinson I, Dawes M, Rafi D, Pirmohamed M and Walter F. The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities. J. Community Genet. (2020) 11: 269-77.

This article is available online at http://www.ijpr.ir